Compare GE Vernova Inc (GEV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Pfizer Inc — how do they compare? GE Vernova Inc trades at $1,001.16 (market cap $266.16B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Pfizer Inc for 158 Days on average.
| GEV | PFE | |
|---|---|---|
Market Cap | $266.16B | $158.56B |
Volume | 2,324,165 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $1.17K | $29.02 |
52-Week Low | $547.96 | $23.67 |
Typical Hold Time | 36 Days | 158 Days |
Enterprise Value | $255.83B | $210.06B |
Dividend Yield | 0.2% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent Q1 2026 earnings beat expectations with $17.44 EPS, though Q2 missed. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and execution challenges in the wind segment. The stock offers 27% upside to consensus target, supported by strong institutional sentiment and AI infrastructure tailwinds.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
